Unintended and in situ amorphisation of pharmaceuticals

Department of Pharmacy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Unintended and in situ amorphisation of pharmaceuticals. / Priemel, P A; Grohganz, H; Rades, T.

In: Advanced Drug Delivery Reviews, Vol. 100, 01.05.2016, p. 126-32.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Priemel, PA, Grohganz, H & Rades, T 2016, 'Unintended and in situ amorphisation of pharmaceuticals', Advanced Drug Delivery Reviews, vol. 100, pp. 126-32. https://doi.org/10.1016/j.addr.2015.12.014

APA

Priemel, P. A., Grohganz, H., & Rades, T. (2016). Unintended and in situ amorphisation of pharmaceuticals. Advanced Drug Delivery Reviews, 100, 126-32. https://doi.org/10.1016/j.addr.2015.12.014

Vancouver

Priemel PA, Grohganz H, Rades T. Unintended and in situ amorphisation of pharmaceuticals. Advanced Drug Delivery Reviews. 2016 May 1;100:126-32. https://doi.org/10.1016/j.addr.2015.12.014

Author

Priemel, P A ; Grohganz, H ; Rades, T. / Unintended and in situ amorphisation of pharmaceuticals. In: Advanced Drug Delivery Reviews. 2016 ; Vol. 100. pp. 126-32.

Bibtex

@article{01992f88d3c44caa98bfc50be0dae9eb,

title = "Unintended and in situ amorphisation of pharmaceuticals",

abstract = "Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.",

keywords = "Journal Article, Review",

author = "Priemel, {P A} and H Grohganz and T Rades",

year = "2016",

month = may,

day = "1",

doi = "10.1016/j.addr.2015.12.014",

language = "English",

volume = "100",

pages = "126--32",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Unintended and in situ amorphisation of pharmaceuticals

AU - Priemel, P A

AU - Grohganz, H

AU - Rades, T

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.

AB - Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.

KW - Journal Article

KW - Review

U2 - 10.1016/j.addr.2015.12.014

DO - 10.1016/j.addr.2015.12.014

M3 - Journal article

C2 - 26724250

VL - 100

SP - 126

EP - 132

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -

ID: 169413698